1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Non-prescription Drugs Revenue
1.4 Market Analysis by Type
1.4.1 Global Non-prescription Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Brand Drugs
1.4.3 Generic Drug
1.5 Market by Application
1.5.1 Global Non-prescription Drugs Market Share by Application: 2021-2026
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Non-prescription Drugs Market
1.8.1 Global Non-prescription Drugs Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Non-prescription Drugs Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Non-prescription Drugs Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Non-prescription Drugs Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Non-prescription Drugs Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Non-prescription Drugs Sales Volume Market Share by Region (2015-2020)
3.2 Global Non-prescription Drugs Sales Revenue Market Share by Region (2015-2020)
3.3 North America Non-prescription Drugs Sales Volume
3.3.1 North America Non-prescription Drugs Sales Volume Growth Rate (2015-2020)
3.3.2 North America Non-prescription Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Non-prescription Drugs Sales Volume
3.4.1 East Asia Non-prescription Drugs Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Non-prescription Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Non-prescription Drugs Sales Volume (2015-2020)
3.5.1 Europe Non-prescription Drugs Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Non-prescription Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Non-prescription Drugs Sales Volume (2015-2020)
3.6.1 South Asia Non-prescription Drugs Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Non-prescription Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Non-prescription Drugs Sales Volume (2015-2020)
3.7.1 Southeast Asia Non-prescription Drugs Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Non-prescription Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Non-prescription Drugs Sales Volume (2015-2020)
3.8.1 Middle East Non-prescription Drugs Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Non-prescription Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Non-prescription Drugs Sales Volume (2015-2020)
3.9.1 Africa Non-prescription Drugs Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Non-prescription Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Non-prescription Drugs Sales Volume (2015-2020)
3.10.1 Oceania Non-prescription Drugs Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Non-prescription Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Non-prescription Drugs Sales Volume (2015-2020)
3.11.1 South America Non-prescription Drugs Sales Volume Growth Rate (2015-2020)
3.11.2 South America Non-prescription Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Non-prescription Drugs Sales Volume (2015-2020)
3.12.1 Rest of the World Non-prescription Drugs Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Non-prescription Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Non-prescription Drugs Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Non-prescription Drugs Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Non-prescription Drugs Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Non-prescription Drugs Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Non-prescription Drugs Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Non-prescription Drugs Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Non-prescription Drugs Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Non-prescription Drugs Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Non-prescription Drugs Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Non-prescription Drugs Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Non-prescription Drugs Sales Volume Market Share by Type (2015-2020)
14.2 Global Non-prescription Drugs Sales Revenue Market Share by Type (2015-2020)
14.3 Global Non-prescription Drugs Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Non-prescription Drugs Consumption Volume by Application (2015-2020)
15.2 Global Non-prescription Drugs Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Non-prescription Drugs Business
16.1 Pfizer
16.1.1 Pfizer Company Profile
16.1.2 Pfizer Non-prescription Drugs Product Specification
16.1.3 Pfizer Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Gilead Sciences
16.2.1 Gilead Sciences Company Profile
16.2.2 Gilead Sciences Non-prescription Drugs Product Specification
16.2.3 Gilead Sciences Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Johnson & Johnson
16.3.1 Johnson & Johnson Company Profile
16.3.2 Johnson & Johnson Non-prescription Drugs Product Specification
16.3.3 Johnson & Johnson Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Roche
16.4.1 Roche Company Profile
16.4.2 Roche Non-prescription Drugs Product Specification
16.4.3 Roche Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 AbbVie
16.5.1 AbbVie Company Profile
16.5.2 AbbVie Non-prescription Drugs Product Specification
16.5.3 AbbVie Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 Sanofi
16.6.1 Sanofi Company Profile
16.6.2 Sanofi Non-prescription Drugs Product Specification
16.6.3 Sanofi Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 Amgen
16.7.1 Amgen Company Profile
16.7.2 Amgen Non-prescription Drugs Product Specification
16.7.3 Amgen Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 Novartis
16.8.1 Novartis Company Profile
16.8.2 Novartis Non-prescription Drugs Product Specification
16.8.3 Novartis Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.9 Merck & Co. (MSD)
16.9.1 Merck & Co. (MSD) Company Profile
16.9.2 Merck & Co. (MSD) Non-prescription Drugs Product Specification
16.9.3 Merck & Co. (MSD) Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.10 GlaxoSmithKline (GSK)
16.10.1 GlaxoSmithKline (GSK) Company Profile
16.10.2 GlaxoSmithKline (GSK) Non-prescription Drugs Product Specification
16.10.3 GlaxoSmithKline (GSK) Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.11 Bayer
16.11.1 Bayer Company Profile
16.11.2 Bayer Non-prescription Drugs Product Specification
16.11.3 Bayer Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.12 Takeda
16.12.1 Takeda Company Profile
16.12.2 Takeda Non-prescription Drugs Product Specification
16.12.3 Takeda Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.13 AstraZeneca
16.13.1 AstraZeneca Company Profile
16.13.2 AstraZeneca Non-prescription Drugs Product Specification
16.13.3 AstraZeneca Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.14 Takeda
16.14.1 Takeda Company Profile
16.14.2 Takeda Non-prescription Drugs Product Specification
16.14.3 Takeda Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.15 Novo Nordisk
16.15.1 Novo Nordisk Company Profile
16.15.2 Novo Nordisk Non-prescription Drugs Product Specification
16.15.3 Novo Nordisk Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.16 Teva
16.16.1 Teva Company Profile
16.16.2 Teva Non-prescription Drugs Product Specification
16.16.3 Teva Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.17 Bristol-Myers Squibb
16.17.1 Bristol-Myers Squibb Company Profile
16.17.2 Bristol-Myers Squibb Non-prescription Drugs Product Specification
16.17.3 Bristol-Myers Squibb Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.18 Boehringer Ingelheim
16.18.1 Boehringer Ingelheim Company Profile
16.18.2 Boehringer Ingelheim Non-prescription Drugs Product Specification
16.18.3 Boehringer Ingelheim Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.19 Allergan
16.19.1 Allergan Company Profile
16.19.2 Allergan Non-prescription Drugs Product Specification
16.19.3 Allergan Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.20 Eli Lilly
16.20.1 Eli Lilly Company Profile
16.20.2 Eli Lilly Non-prescription Drugs Product Specification
16.20.3 Eli Lilly Non-prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Non-prescription Drugs Manufacturing Cost Analysis
17.1 Non-prescription Drugs Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Non-prescription Drugs
17.4 Non-prescription Drugs Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Non-prescription Drugs Distributors List
18.3 Non-prescription Drugs Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Non-prescription Drugs (2021-2026)
20.2 Global Forecasted Revenue of Non-prescription Drugs (2021-2026)
20.3 Global Forecasted Price of Non-prescription Drugs (2015-2026)
20.4 Global Forecasted Production of Non-prescription Drugs by Region (2021-2026)
20.4.1 North America Non-prescription Drugs Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Non-prescription Drugs Production, Revenue Forecast (2021-2026)
20.4.3 Europe Non-prescription Drugs Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Non-prescription Drugs Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Non-prescription Drugs Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Non-prescription Drugs Production, Revenue Forecast (2021-2026)
20.4.7 Africa Non-prescription Drugs Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Non-prescription Drugs Production, Revenue Forecast (2021-2026)
20.4.9 South America Non-prescription Drugs Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Non-prescription Drugs Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Non-prescription Drugs by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Non-prescription Drugs by Country
21.2 East Asia Market Forecasted Consumption of Non-prescription Drugs by Country
21.3 Europe Market Forecasted Consumption of Non-prescription Drugs by Countriy
21.4 South Asia Forecasted Consumption of Non-prescription Drugs by Country
21.5 Southeast Asia Forecasted Consumption of Non-prescription Drugs by Country
21.6 Middle East Forecasted Consumption of Non-prescription Drugs by Country
21.7 Africa Forecasted Consumption of Non-prescription Drugs by Country
21.8 Oceania Forecasted Consumption of Non-prescription Drugs by Country
21.9 South America Forecasted Consumption of Non-prescription Drugs by Country
21.10 Rest of the world Forecasted Consumption of Non-prescription Drugs by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer